NCT01678105 - A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Recurrent Adenoid Cystic Carcinoma of the Salivary GlandsMetastatic Adenoid Cystic Carcinoma of the Salivary GlandsSalivary Gland CancersACC

Interventions

DRUG

Dovitinib

Treatment continued until Disease Progression, Toxicity, or patient withdrawal

Trial Locations (4)

Tom Baker Cancer Centre, Calgary

Juravinski Cancer Centre, Hamilton

London Health Sciences Centre, London

Ottawa Hospital Regional Cancer Centre, Ottawa